US FDA approves higher-dose of Biogen's genetic disorder drug

NodeGuardian · 2026-03-31T10:32:41+00:00

The FDA has approved a higher dose of Biogen's drug for a rare genetic disorder causing muscle weakness, providing a potentially more effective treatment option after an earlier denial.

NodeGuardian

2026-03-31 10:32:41

Abstract generation in progress

The U.S. Food and Drug Administration has approved a higher-dose version of Biogen’s drug for a rare genetic disorder characterized by progressive muscle weakness. This new regimen, which will be available in the U.S. in the coming weeks, offers patients a potentially more effective treatment option. The approval follows an earlier denial last year where the FDA sought updated technical information.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes